The effect of PPE-induced emphysema and chronic LPS-induced pulmonary inflammation on atherosclerosis development in APOE*3-LEIDEN mice

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Khedoe, P Padmini S J ^a   Wong, Man C ^a   Wagenaar, Gerry T M ^a   Plomp, Jaap J ^a   Van Eck, Miranda ^b   Havekes, Louis M ^a,c   Rensen, Patrick C N ^a   Hiemstra, Pieter S ^a   Berbée, Jimmy F P ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E3; BLOOD CLOTTING FACTOR 5 LEIDEN; CHOLESTEROL; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PANCREATIC ELASTASE; PHOSPHOLIPID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE RELEASE; HYPERLIPIDEMIA; LUNG EMPHYSEMA; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; PNEUMONIA; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEIN E3; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATION MEDIATORS; LIPIDS; LIPOPOLYSACCHARIDES; MICE; MICE, TRANSGENIC; PANCREATIC ELASTASE; PNEUMONIA; PULMONARY EMPHYSEMA;

EID: 84896727924     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080196     Document Type: Article

References (43)

1. Brusselle GG, Joos GF, Bracke KR (2011) New insights into the immunology of chronic obstructive pulmonary disease. Lancet 378: 1015-1026. S0140-6736(11)60988-4 [pii];10.1016/S0140-6736(11)60988-4 [doi].
2. Sin DD, Man SF (2003) Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107: 1514-1519. (Pubitemid 36378490)
3. Gairola CG, Drawdy ML, Block AE, Daugherty A (2001) Sidestream cigarette smoke accelerates atherogenesis in apolipoprotein E-/- mice. Atherosclerosis 156: 49-55. S0021-9150(00)00621-3 [pii].
4. von Holten K, Lebrun S, Stinn W, Conroy L, Wallerath T, et al. (2009) Progression of atherosclerosis in the Apo E-/- model: 12-month exposure to cigarette mainstream smoke combined with high-cholesterol/fat diet. Atherosclerosis 205: 135-143. S0021-9150(08)00815-0 [pii];10.1016/j. atherosclerosis.2008.11.031 [doi].
5. Andrus MR, Loyed JV (2008) Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular comorbidity: safety issues. Drugs Aging 25: 131-144. 2525 [pii].
6. Agusti A, Soriano JB (2008) COPD as a systemic disease. COPD 5: 133-138. 792177097 [pii];10.1080/15412550801941349 [doi].
7. Agusti A, Edwards LD, Rennard SI, Macnee W, Tal-Singer R, et al. (2012) Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 7: e37483. 10.1371/journal.pone. 0037483 [doi];PONE-D-12-05051 [pii].
8. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, et al. (2003) Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 21: 347-360. (Pubitemid 36204553)
9. Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, et al. (2008) The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177: 1207-1214. (Pubitemid 351860929)
10. Loke YK, Kwok CS, Singh S (2010) Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur Respir J 35: 1003-1021.
11. Hurst JR, Wilkinson TM, Perera WR, Donaldson GC, Wedzicha JA (2005) Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest 127: 1219-1226. 127/4/1219 [pii];10.1378/chest.127. 4.1219 [doi].
12. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, et al. (2002) Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 166: 1218-1224. (Pubitemid 35222599)
13. Johannessen A, Skorge TD, Bottai M, Grydeland TB, Nilsen RM, et al. (2013) Mortality by Level of Emphysema and Airway Wall Thickness. Am J Respir Crit Care Med. rccm.201209-1722OC [pii];10.1164/rccm.201209-1722OC [doi].
14. Martinez FJ, Foster G, Curtis JL, Criner G, Weinmann G, et al. (2006) Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 173: 1326-1334. 200510-1677OC [pii];10.1164/rccm.200510-1677OC [doi].
15. Vernooy JH, Dentener MA, van Suylen RJ, Buurman WA, Wouters EF (2002) Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol 26: 152-159. (Pubitemid 34029832)
16. Hayes JA, Korthy A, Snider GL (1975) The pathology of elastase-induced panacinar emphysema in hamsters. J Pathol 117: 1-14. 10.1002/path.1711170102 [doi].
17. Zadelaar AS, Boesten LS, Jukema JW, van Vlijmen BJ, Kooistra T, et al. (2006) Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulinresistant and hypercholesterolemic ApoE*3Leiden mice. Arterioscler Thromb Vasc Biol 26: 2560-2566. 01.ATV.0000242904.34700.66 [pii];10.1161/01.ATV. 0000242904.34700.66 [doi].
18. Lucey EC, Keane J, Kuang PP, Snider GL, Goldstein RH (2002) Severity of elastase-induced emphysema is decreased in tumor necrosis factor-alpha and interleukin-1beta receptor-deficient mice. Lab Invest 82: 79-85. (Pubitemid 34072648)
19. Luthje L, Raupach T, Michels H, Unsold B, Hasenfuss G, et al. (2009) Exercise intolerance and systemic manifestations of pulmonary emphysema in a mouse model. Respir Res 10: 7.
20. van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, van der Boom H, HogenEsch H, et al. (1994) Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 93: 1403-1410. 10.1172/JCI117117 [doi]. (Pubitemid 24116375)
21. Zitman FM, Todorov B, Jacobs BC, Verschuuren JJ, Furukawa K, et al. (2008) Neuromuscular synaptic function in mice lacking major subsets of gangliosides. Neuroscience 156: 885-897.
22. de Visser YP, Walther FJ, Laghmani EH, Boersma H, van der Laarse A, et al. (2009) Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. Respir Res 10: 30.
23. van der Hoorn JW, Jukema JW, Havekes LM, Lundholm E, Camejo G, et al. (2009) The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. Br J Pharmacol 156: 1067-1075.
24. Westerterp M, Berbee JF, Pires NM, van Mierlo GJ, Kleemann R, et al. (2007) Apolipoprotein C-I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice. Circulation 116: 2173-2181.CIRCULATIONAHA.107.693382 [pii]; 10.1161/CIRCULATIONAHA.107.693382 [doi].
25. Han SG, Howatt DA, Daugherty A, Gairola CG (2012) Atherogenic and pulmonary responses of ApoE- and LDL receptor-deficient mice to sidestream cigarette smoke. Toxicology 299: 133-138. S0300-483X(12)00171-0 [pii];10.1016/j.tox.2012.05.015 [doi].
26. Arunachalam G, Sundar IK, Hwang JW, Yao H, Rahman I (2010) Emphysema is associated with increased inflammation in lungs of atherosclerosis-prone mice by cigarette smoke: implications in comorbidities of COPD. J Inflamm (Lond) 7: 34. 1476-9255-7-34 [pii];10.1186/1476-9255-7-34 [doi].
27. Fu Y, Glaros T, Zhu M, Wang P, Wu Z, et al. (2012) Network topologies and dynamics leading to endotoxin tolerance and priming in innate immune cells. PLoS Comput Biol 8: e1002526. 10.1371/journal.pcbi.1002526 [doi]; PCOMPBIOL-D-11-01777 [pii].
28. Tamagawa E, Suda K, Wei Y, Xing L, Mui T, et al. (2009) Endotoxin-induced translocation of interleukin-6 from lungs to the systemic circulation. Innate Immun 15: 251-258. 1753425909104782 [pii];10.1177/1753425909104782 [doi].
29. Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, et al. (2012) Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol 32: 281-290. ATVBAHA.111.229435 [pii];10.1161/ATVBAHA.111.229435 [doi].
30. Boesten LS, Zadelaar AS, van NA, Gijbels MJ, de Winther MP, et al. (2005) Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-Leiden transgenic mice. Cardiovasc Res 66: 179-185. S0008-6363(05)00019-2 [pii];10.1016/j.cardiores.2005.01.001 [doi].
31. Hulten LM, Levin M (2009) The role of hypoxia in atherosclerosis. Curr Opin Lipidol 20: 409-414. 10.1097/MOL.0b013e3283307be8 [doi].
32. Chaouat A, Naeije R, Weitzenblum E (2008) Pulmonary hypertension in COPD. Eur Respir J 32: 1371-1385.
33. Tkacova R (2010) Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives. Mediators Inflamm 2010: 585989. 10.1155/2010/585989 [doi].
34. Rutten EP, Grydeland TB, Pillai SG, Wagers S, Dirksen A, et al. (2011) Quantitative CT: Associations between Emphysema, Airway Wall Thickness and Body Composition in COPD. Pulm Med 2011: 419328. 10.1155/2011/419328 [doi].
35. Ogawa E, Nakano Y, Ohara T, Muro S, Hirai T, et al. (2009) Body mass index in male patients with COPD: correlation with low attenuation areas on CT. Thorax 64: 20-25. thx.2008.097543 [pii];10.1136/thx.2008.097543 [doi].
36. Cherepanova OA, Pidkovka NA, Sarmento OF, Yoshida T, Gan Q, et al. (2009) Oxidized phospholipids induce type VIII collagen expression and vascular smooth muscle cell migration. Circ Res 104: 609-618. CIRCRESAHA. 108.186064 [pii];10.1161/CIRCRESAHA.108.186064 [doi].
37. Adiguzel E, Ahmad PJ, Franco C, Bendeck MP (2009) Collagens in the progression and complications of atherosclerosis. Vasc Med 14: 73-89. 14/1/73 [pii];10.1177/1358863X08094801 [doi].
38. Lopes J, Adiguzel E, Gu S, Liu SL, Hou G, et al. (2013) Type VIII collagen mediates vessel wall remodeling after arterial injury and fibrous cap formation in atherosclerosis. Am J Pathol 182: 2241-2253. S0002-9440(13)00188-0 [pii];10.1016/j.ajpath.2013.02.011 [doi].
39. Barnes MJ, Farndale RW (1999) Collagens and atherosclerosis.Exp Gerontol 34: 513-525. S0531-5565(99)00038-8 [pii].
40. Lamberts RR, Vaessen RJ, Westerhof N, Stienen GJ (2007) Right ventricular hypertrophy causes impairment of left ventricular diastolic function in the rat. Basic Res Cardiol 102: 19-27. 10.1007/s00395-006-0620-5 [doi]. (Pubitemid 44932768)
41. Garcia M, Kassab GS (2009) Right coronary artery becomes stiffer with increase in elastin and collagen in right ventricular hypertrophy. J Appl Physiol 106: 1338-1346. 90592.2008 [pii];10.1152/japplphysiol.90592.2008 [doi].
42. Buccino RA, Harris E, Spann JF, Jr., Sonnenblick EH (1969) Response of myocardial connective tissue to development of experimental hypertrophy. Am J Physiol 216: 425-428.
43. Rekhter MD, Zhang K, Narayanan AS, Phan S, Schork MA, et al. (1993) Type I collagen gene expression in human atherosclerosis. Localization to specific plaque regions. Am J Pathol 143: 1634-1648. (Pubitemid 24058267)